A Rare Case of Desmoplastic Mesothelioma With Good Survival Despite Lymph Node Metastasis

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S43-S43
Author(s):  
Atreyee Basu ◽  
Harvey Pass ◽  
Fang Zhou ◽  
Navneet Narula ◽  
Andre Moreira

Abstract Introduction Desmoplastic mesothelioma (DMM), a rare histological subtype of malignant pleural mesothelioma (MPM), is lethal and has very poor prognosis. Metastasis is commonly reported in DMM compared to other histological subtypes. Here we report a case of DMM with good survival (>1 year) despite lymph node metastasis. Case Report A 62-year-old female with a history of smoking and possible asbestos exposure presented with cough and wheeze in 2012. Computed tomography (CT) revealed left-sided pleural plaques and multiple ground-glass pulmonary nodules. In 2017, repeat CT showed increased diffuse left nodular pleural thickening. Positron emission tomography revealed hypermetabolic, nodular pleural thickening in the hemithorax, compatible with neoplasia. Needle biopsy in January 2018 showed pleural tissue with haphazard, nodular growth of spindled mesothelial cells, suspicious for desmoplastic mesothelioma. Definitive diagnosis was not possible due to lack of fat invasion and absence of supportive evidence by immunohistochemical stains. The patient underwent pleurectomy in February 2018. On histopathology, the majority of the tumor showed a desmoplastic pattern, composed of malignant spindled cells arranged haphazardly in a dense hyalinized stroma with chronic inflammatory infiltrate. AE1/AE3, calretinin, and D2-40 immunohistochemical stains highlighted the infiltrating neoplastic cells, which were negative for WT-1. BAP-1 was retained. The pattern of immunoreactivity supported the diagnosis of DMM. The tumor also involved visceral pleura, pulmonary parenchyma, and pericardium. It invaded into fat and displayed lymphovascular invasion. A metastatic focus of DMM was present in a lymph node. The tumor was staged as pT3N1. On recent examination, the patient only had complaints of mild breathlessness and stable hydro-pneumothorax, without any other comorbidities. Conclusion Our finding is unusual, since among the mesothelioma subtypes, DMM has the shortest survival, usually not more than 6 months. We report an extremely rare case of DMM with survival of >1 year despite invasion of lung parenchyma and lymph node metastasis.

2017 ◽  
Vol 5 (2) ◽  
pp. 2292-2294
Author(s):  
Vasudha singh ◽  
◽  
Vinita Trivedi ◽  
Richa Chauhan ◽  
Manashi ghosh ◽  
...  

2018 ◽  
Vol 90 (4) ◽  
pp. 218-220
Author(s):  
Alexander M Nixon ◽  
S Roditis ◽  
D Bouklas ◽  
C Aggeli ◽  
A Kostopoulou ◽  
...  

2010 ◽  
Vol 5 (1) ◽  
pp. 27 ◽  
Author(s):  
Yoichiro Okubo ◽  
Tomoyuki Yokose ◽  
Masaru Tuchiya ◽  
Aki Mituda ◽  
Megumi Wakayama ◽  
...  

2019 ◽  
Vol 52 (4) ◽  
pp. 369-372
Author(s):  
Takaaki Yoshikawa ◽  
Yoshio Kadokawa ◽  
Masaya Ohana ◽  
Akihisa Fukuda ◽  
Hiroshi Seno

Oncotarget ◽  
2018 ◽  
Vol 9 (12) ◽  
pp. 10808-10817 ◽  
Author(s):  
Naoki Ikari ◽  
Shota Aoyama ◽  
Akiyoshi Seshimo ◽  
Yuji Suehiro ◽  
Tomoko Motohashi ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Yanyang Liu ◽  
Lang Long ◽  
Jiewei Liu ◽  
Lingling Zhu ◽  
Feng Luo

BackgroundPrimary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer (NSCLC). Currently, anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) has become an important treatment for NSCLC. Anti-human PD-1 monoclonal antibodies, such as nivolumab, significantly prolong the survival time of patients with advanced lung adenocarcinoma and lung squamous cell carcinoma. However, there are few reports on the therapeutic effect, drug resistance mechanism, and strategies to overcome resistance to anti-PD-1/PD-L1 treatment in advanced pulmonary LELC. We report the case of a patient with advanced pulmonary LELC harboring fibroblast growth factor receptor (FGFR)3 gene amplification that showed resistance to nivolumab. After treatment with anlotinib, a multi-targeted small-molecule tyrosine kinase inhibitor, the patient’s resistance to nivolumab was reversed. She achieved long-term disease remission with a combination of anlotinib and nivolumab treatment.Case PresentationA 68-year-old woman was diagnosed with stage IVA pulmonary LELC. After multiple-line chemotherapy, her disease progressed. Since the PD-L1 expression rate of the patient was 90%, nivolumab was administered. However, the therapeutic effect of nivolumab was not ideal; the disease continued to progress, and a new cervical lymph node metastasis appeared. FGFR3 gene amplification was detected in lymph node metastasis. Based on this gene abnormality, we added anlotinib to the treatment. After two cycles of anlotinib and nivolumab, the metastatic focus of the patient was significantly reduced. The patient continued to receive this combined treatment and achieved remission for more than 15 months.ConclusionPulmonary LELC with FGFR3 gene amplification may not respond well to nivolumab monotherapy. The combination of anlotinib and nivolumab can reverse the resistance to nivolumab in pulmonary LELC with FGFR3 gene amplification.


Sign in / Sign up

Export Citation Format

Share Document